A Post-marketing, Observational, Retrospective Study to Assess the Safety of RefortrixTM (Tdap) When Administered During Pregnancy in a Maternal Immunization Program in Brazil.

GlaxoSmithKline2,462 enrolled

Overview

The purpose of this study is to assess the safety of RefortrixTM (Tdap) when administered during pregnancy in a maternal immunization program in Brazil.

In this retrospective cohort study the safety of RefortrixTM (Tdap) administered during pregnancy as part of the National immunization program in Brazil will be assessed by comparing the risk of pre-defined adverse events before and after introduction of the RefortrixTM (Tdap) maternal immunization program.

Study Type

OBSERVATIONAL

Enrollment

2,462

Conditions

Diphtheria

Interventions

Combined diphtheria, tetanus and tricomponent acellular pertussis vaccine [Refortrix (Tdap)]BIOLOGICAL

Subjects were included in the Exposed cohort if they received Refortrix as part of the maternal immunization program in Brazil.

Eligibility

Sex: FEMALEMin age: 18 YearsMax age: 45 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Subjects between 18 and 45 years of age at the time of pregnancy under consideration for the study, who deliver in the study centre. * Residents of the study area * Subjects who were compliant with the routine antenatal care including at least one ultrasound assessment report early in the pregnancy. * Subjects with the complete and relevant medical records available. Inclusion criteria for the Exposed cohort: * Subjects who received one dose of Refortrix vaccine in the recommended time period between 27 and 36 completed weeks of pregnancy (or as late as 20 days before delivery due date) as part of the maternal immunization program in Brazil, and according to the program recommendations from May 2015 onwards. * Subjects with appropriate vaccination records. Inclusion criteria for the Unexposed cohort: * Subjects who had delivered in the same hospital (study centre) before 01 September 2014 (September 2012-August 2014) and who did not receive Tdap vaccination during pregnancy to the best knowledge of the investigator. Exclusion Criteria: * Subjects who have been transferred to other specialised centres, where their medical records would be inaccessible for the study (private clinics, psychiatric or prison hospitals, other state hospitals, etc).

Locations (1)

GSK Investigational Site

Santo André, São Paulo, Brazil

Outcomes

Primary Outcomes

Number of Subjects Reporting Gestational Diabetes

Gestational diabetes was defined as: Onset or first recognition of abnormal glucose tolerance during pregnancy (the diagnosis is based on administration of glucose challenge test at 24-28 weeks of gestation). Includes Class A1: Euglycaemia achieved with diet and/or exercise and Class A2: Euglycaemia achieved with medication.

Time frame: After week 27 of pregnancy

Number of Subjects Reporting Pregnancy-related Hypertension, Pre-eclampsia, Eclampsia, and HELLP Syndrome

Pregnancy-related hypertension is defined as: Blood pressure systolic higher than (\>) 140 and/or diastolic \> 90 millimetre of mercury (mmHg), documented in at least two separate measurements after 20 weeks of gestation, without proteinuria or other stigmata of pre-eclampsia, and returning to normal post-partum. Hypertension usually resolves by 12 weeks post-partum, included pre-eclampsia, eclampsia and haemolysis elevated liver enzymes low platelet (HELLP) Syndrome for this study.

Time frame: After week 27 of pregnancy

Number of Subjects Reporting Pregnancy Hemorrhage

Pregnancy vaginal hemorrhage is defined as: excessive blood loss after delivery i.e. estimated blood loss in excess of 500 milliliters (ml) after vaginal delivery and estimated blood loss in excess of 1000 ml after Caesarean delivery. The other symptoms are higher than or equal to (≥) 10 percent (%) drop in hematocrit, need for blood transfusion, symptomatic hypotension, dizziness, pallor and oliguria. Vaginal or intrauterine hemorrhage that encompasses antepartum (i.e. bleeding from the genital tract after 24 weeks of gestation), intrapartum, and postpartum bleeding (i.e. within 24 hours post-delivery). A major obstetric hemorrhage is defined as blood loss from uterus or genital tract \>1500 ml or a decrease.

Time frame: After week 27 of pregnancy

Number of Subjects With Pre-specified Neonate-related Outcomes Resulting in Preterm Birth

Preterm birth is defined as: Birth before 37 weeks of gestation.

Time frame: From week 27 up to week 37 of pregnancy

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.

Secondary Outcomes

Number of Subjects Reporting Pregnancy-related Adverse Events (AEs) of Interest/Neonate-related Events up to Delivery

Pregnancy-related AEs of interest and neonate-related events are defined as: premature rupture of membranes, preterm premature rupture of membranes, premature uterine contraction, neonatal death, maternal death, still birth, neonatal hypoxic ischaemic encephalopathy.

Time frame: After week 27 of pregnancy

Number of Subjects Reporting Cases of Congenital Anomalies in the Neonates

Congenital anomalies include morphological, functional, chromosomal or genetic anomalies, regardless of whether detected at birth or not, the foetus is delivered dead or alive, or defects are identified by prenatal ultrasound, amniocentesis or examination of the products of conception.

Time frame: From week 27 of pregnancy up to birth

Number of Subjects With Pregnancy-related AEs and Birth Outcomes Per Calendar Year

Pregnancy related AEs include: gestational diabetes, pregnancy-related hypertension, pre-eclampsia, eclampsia, HELLP Syndrome and pregnancy hemorrhage. Birth outcomes include: preterm birth and small for gestational age.

Time frame: After week 27 of pregnancy